Chronic Hepatitis B Drug Development Summit
5-6 May, 2021
Pietro Scalfaro, our CMO, will present clinical results of our lead compound Vonafexor at the Chronic Hepatitis B Drug Development Summit : “Targeting the Farnesoid X Receptor for the Treatment of Chronic Hepatitis B”.
This Summit is the first-ever dedicated digital industry forum dedicated exclusively to the frontier of drug development in Chronic HBV. The two-day program explores the full spectrum of antiviral & immunomodulatory agents being investigated to achieve a functional cure in chronic HBV infection & mitigate related conditions such as fibrosis, cirrhosis, & hepatocellular carcinoma.
More details here: https://chronic-hbv-summit.com/